|  |
| --- |
| September 24, 2015 |
|  |
| Contact person specialized pressDr. Jürgen KrauterVice President CommunicationsPhone +49 6181 59-6847Fax +49 6181 59-76847juergen.krauter@evonik.com  |
|  |
| Evonik Nutrition & Care GmbHRellinghauser Straße 1-1145128 EssenTelefone +49 201 177-01Telefax +49 201 177-3475Germanywww.evonik.com**Supervisory Board**Dr. Ralph Sven Kaufmann, ChairmanManagement BoardDr. Reiner Beste, ChairmanDr. Hans Josef RitzertMichael GattermannMarkus SchäferRegistered office EssenRegistered courtEssen local courtCommercial registry B 25784HR no. FN 431387 v |

**Price increase for pharmaceutical excipients and bioresorbable medical device polymers**

Essen, Germany. Evonik Nutrition & Care GmbH will implement price increases for its pharmaceutical excipients and medical device polymers sold under the EUDRAGIT® and RESOMER® brands. This price adjustment is necessary to maintain the high level of service and quality Evonik customers are accustomed to.

Evonik is committed to investments that enhance the quality and availability of supplies and services, exemplified by its increasing network of technical support centers and personnel, which support its customers’ growth.

**About Nutrition & Care**

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around €4.2 billion in 2014.

**About Evonik**

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2014 more than 33,000 employees generated sales of around €12.9 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.